Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis
NCT04675619Phase 2Completed
- Sponsor
- Zagazig University
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirfenidone in chronic hypersensitivity pneumonitis (cHP) (2 arms), sponsored by Zagazig University. Primary endpoints: Forced Vital Capacity at 6 months and 6-Minute Walk Distance at 6 months. Started Dec 2019; status: completed.
02
Drugs
pirfenidone
03
Conditions
chronic hypersensitivity pneumonitis (cHP)
Beyond the preview
Go deeper on NCT04675619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675619.